SBC Medical Group Holdings (SBC) Emerging Growth Conference 93 summary
Event summary combining transcript, slides, and related documents.
Emerging Growth Conference 93 summary
11 Jun, 2026Business model and operations
Operates as a medical services organization, providing centralized support to clinics across multiple healthcare fields, using an asset-light franchise model due to Japanese regulations.
Portfolio includes over 20 brands, covering aesthetic, dermatology, orthopedics, fertility, gynecology, dentistry, alopecia, and ophthalmology, serving 6.7 million customers annually through 284 clinics.
Multi-brand strategy enables targeting diverse patient needs and maintaining long-term relationships, with 72% repeat rate and strong customer loyalty.
Franchise model features fixed and variable fees, equipment leasing, and procurement revenue, with clinics reaching profitability in 5-6 months.
No franchise agreement has ever been terminated in 26 years, highlighting model durability.
Financial performance and resilience
Q1 2026 revenue was $43 million, a 9% YoY decline due to fee structure revisions, but underlying revenue grew 11% YoY when adjusted for these changes.
Underlying EBITDA increased 17% YoY after adjusting for fee structure revisions.
Average revenue per visit rebounded to JPY 316 in Q4 2025, up 11% YoY, following strategic pricing and multi-branding adjustments.
Business demonstrated resilience during COVID-19 and benefited from tighter Japanese regulations, strengthening its market position.
EBITDA margin exceeds 40%, with net income up 9% YoY to JPY 51 million last year.
Growth strategy and initiatives
Four key initiatives: launch of SBC Wellness 2.0 focused on longevity, expansion into non-aesthetic medical fields, disciplined global expansion, and AI-driven operational transformation.
SBC Wellness 2.0 targets the $34 billion Japanese longevity market, leveraging corporate B2B channels for scalable growth.
Applying proven operational playbook to new fields like AGA, dentistry, orthopedics, fertility, and ophthalmology.
Global expansion is selective, with Japan as the core; U.S. growth pursued via partnership with OrangeTwist and further opportunities in Southeast Asia.
Goal to increase global business from 1% to 25% of revenue within five years.
Latest events from SBC Medical Group Holdings
- Underlying growth, AI-driven efficiency, and longevity-focused expansion drive future prospects.SBC
Sidoti Small-Cap Virtual Investor Conference18 Jun 2026 - Largest aesthetic clinic network in Japan, expanding globally with high growth and profitability.SBC
Investor presentation11 Jun 2026 - Scalable clinic network drives growth with data-driven efficiency and a focus on longevity.SBC
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference3 Jun 2026 - Key votes include director elections, auditor ratification, and major governance amendments.SBC
Proxy filing28 May 2026 - Shareholders will vote on director elections, auditor ratification, and major charter amendments.SBC
Proxy filing28 May 2026 - Shareholders will vote on director elections, auditor ratification, and major charter amendments.SBC
Proxy filing15 May 2026 - Q1 2026 revenue and net income declined, but underlying growth and liquidity remained strong.SBC
Q1 202614 May 2026 - Net income and EPS rose in 2025 despite revenue declines, with growth expected in 2026.SBC
Q4 20257 Apr 2026 - Scalable multi-brand medical group achieves rapid global growth and high customer retention.SBC
Corporate presentation27 Mar 2026